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and the Nashville Veterans Affairs Hospital from 1994 to 2002. 
Central pathologic review was performed on biopsies from 12 
patients. All but two patients presented with advanced stage at 
diagnosis. Median age at transplant for the autologous and allo- 
geneic groups was 53.5 and 49.5 years, respectively. A total of 17 
autologous, 1 syngeneic, and 6 alIogeneic transplants were per- 
formed. Five patients underwent autologous transplantation in 
first complete remission. Results: In the autologous group, median 
overall survival was 4.75 years (95% C.I. 3.7 to 5.8y) and median 
survival from transplant was 2.5 years (95% C.I. 1.3 to 3.7y). The 
Kaplan-Meier estimate of 5-year overall survival was 41% (95% 
C.I. 10% to 72%). in the allogeneic group, 4 patients have died. 
Post-transplant survival ranged from 13 days to 3.4 years. 
Chemosensitivity, defined as the maintenance of at least a partial 
response after the last chemotherapy regimen until the date of 
autologous transplant, was associated with improved overall sur- 
vival by log-rank analysis (p=.0005). For these 13 patients the esti- 
mated 5-year overall survival was 56% (95% C.I. 17% to 95%). 
Post-transplant survival was also significantly prolonged in this 
group (median 3.5 years vs. 319 days, p<.0001, 95% C.I. 1.6 to 
5.4y vs. 26d to 1.Ty). Conclusions: The longest overall survival 
occurred in patients with chemosensitive disease who received 
autologous transplantation. Neither the use of total-body irradia- 
tion, fewer than four pre transplant chemotherapy regimens, nor 
transplant in first remission was found to predict for improved 
survival. Although the confidence intervals are wide, these results 
support he hypothesis that patients with chemosensitive mantle 
cell lymphoma may realize a significant survival benefit from 
autologous transplantation. 
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Previous studies in multiple lnyeloma have demonstrated a 
significant association between survival and baseline l vels of 
T cells prior to chemotherapy (Kay et al., Blood 200l) as well 
as lymphocyte counts 15 days following autologous transplan- 
tation (Porrata et al., Blood 2001). Therefore, infusion of large 
numbers of T cells post transplant may improve clinical 
results. We have developed the Xcellerate TM process for the ex 
vivo activation and expansion of T cells using immobilized 
anti-CD3 and anti-CD28 antibodies covalently linked to mag- 
netic beads (Dynabeads® M-450 CD3/CD28 T). Twenty-two 
expansions have been conducted to date using samples from 
multiple myeloma patients who have received avariety of prior 
therapies. The number of T cells increased a mean of 404 fold 
foIlowing an 8-14 day culture process. Purity and viability of T 
ceils post-Xcellerate averaged 97% and 96%, respectively. The 
CD4/CD8 ratio increased from 1.3to 2.1 during the course of 
culture. Significant upregulation of key surface/effector mole- 
cules, including CD25 (IL-2 receptor) and CD154 (CD40 fig- 
and) occurred. Moreover, we have developed a flow cytome- 
try-based assay system for evaluating residual plasma cells in 
the final T cell product. Using analysis of surface marker 
expression, including CD38, CD138, CD45 and CD56, we 
have been unable to detect any plasma cells in the final prod- 
uct within the limits of detection of'the assay (~0.01%). Based 
upon these data, we have initiated a clinical trial to evaluate 
the activity of Xcellerated T Cells in patients with multiple 
myeloma, who are undergoing an autologous stem cell trans- 
plantation. Following induction chemotherapy, patients will 
undergo a leukapheresis to collect T cells for the Xcellerate 
Process. Patients will then undergo stem cell mobilization and 
collection, follwed by high dose chemotherapy with Melpha- 
lan. Patients will then receive a stem cell infusion, followed 
three days later by an infusion of 5-10 x 10 l° autologous 
Xcellerated T Cells. 
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Gene transfer to hematopoietic stem ceils (HSC) may provide 
new treatments for genetic diseases of blood cells that are more 
effective or safer than current approaches using allogeneic trans- 
plantation. Retroviral vectors have been used most often to obtain 
stable gene transfer to HSC and there has been incremental 
progress in the design and production of retroviral vectors and in
the methods used to transduce human HSC. Nevertheless, the 
percentages of reconstituting stem cells that can be transduced in
the clinical setting have been too low to be of benefit in most dis- 
orders (e.g.0.01-1%). However, immune deficiencies, including 
severe combined immune deficiency (SCID) and AIDS, may be 
benefited by gene transfer levels in that range, because the gene- 
modified T lymphocytes may have a selective production or sur- 
vival advantage, compared to the non-corrected cells. The high 
rate of immune reconstitution (90%) in subjects with XSCID 
treated with gene transfer firmly demonstrates the benefits of this 
approach. However, the development of a monoclonal T lympho- 
proliferation in one subject underscores the potential toxicities of 
this approach. We are performing a clinical trial for subjects with 
ADA deficient SCID. Four subjects (ages 4-20 years) have been 
enrolled and have undergone the procedure of bone marrow har- 
vest, CD34+ cell isolation, retroviral-mediated ADA gene trans- 
duction, and cell re-infizsion, without serious adverse vent. The 
subjects did not receive marrow cytoreductive conditioning before 
the cell re-infusion and have all continued to receive PEG-ADA 
enzyme replacement therapy. Follow-up times (thur 10/15/02) are 
currently 13, 12, 9 and 8 months. The transferred ADA gene has 
been detected in peripheral blood samples of all subjects, at fre- 
quencies of between 0.001-3%. A staged withdrawal of enzyme 
replacement may begin after the first year. Clinical trials need to 
be performed to determine the relative benefits and risks of gene 
transfer to HSC as a treatment for SCID, compared to approaches 
using allogeneic HSCT. 
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Herein, we report an adult with TMA associated with HHV-6 
reactivation occurring after ASCT. To our knowledge, this repre- 
sents the first such case in an adult. A 58-year-old female with 
Stage IIIA IgGK multiple myeloma received VAD for 4 cycles fol- 
lowed by" melphalan (200 mg/m2) with ASCT. She was discharged 
on D+16 with resolution of her transplant related toxicities. On 
D+22 she was readmitted with dyspnea, rash, and fever (105 F). 
Despite antibacterial nd antifungal therapy, worsening dyspnea 
and hypotension prompted ICU transfer. Five days later she 
developed TMA and therapeutic plasma exchange (TPE) was ini- 
tiated. Oaa D+28 mental status (MS) changes developed. Head CT 
and EEG were negative. Lumbar puncture (LP) revealed a CSF 
protein of 74. On D+32, a generalized seizure occurred. TPE was 
co~atinued without improvement in thrombocytopenia or her MS 
despite normalization of her LDH, haptoglobin and total biliru 
bin. She required intubation for a depressed MS and another 
seizure. An EEG was consistent with an encephalopathy, and a 
brain MRI showed a right temporal lobe infarct. Serum PCR was 
negative for CMV but positive for HHV-6. Repeat LP demon- 
strated aprotein of 597, a negative CMV antibody, and CSF PCR 
for HSV1, HSV2 were negative but strongly positive for HHV-6 
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